In melanoma, activating BRAF mutations—most notably BRAFV600E and BRAFV600K—drive constitutive MEK activation and sustained ERK phosphorylation, leading to aberrant oncogenic signaling independent of upstream receptor stimulation or external mitogenic cues [132,133]. Here, MAP2K7 is linked to melanoma.